Work

High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.624

Authors: Tanya B. Dorff, Michael K.K. Wong, Joseph Clark, Gregory A. Daniels, Brendan D. Curti, Michael Morse, Howard Kaufman, David F. McDermott, David I. Quinn, Peter Zang, Nancy C. Gregory, Lisa Maria Eifler, Stephen Thomas, Marci White, Jatinder Singh, Janice P. Dutcher

Institutions: University of Southern California, The University of Texas MD Anderson Cancer Center, Loyola University Medical Center, Loyola University Chicago, Moores Cancer Center, Duke Medical Center, Rutgers Cancer Institute, Beth Israel Deaconess Medical Center, USC Norris Comprehensive Cancer Center, Prometheus (United States), Prometheus Biosciences (United States), Lady of Mercy Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2791213928

Cites:

Cited by: 1

Related to: 10